Evercore ISI Analyst Breaks Down Amgen's IPR Against AbbVie's Humira Formulation Patent

By: via Benzinga
Last Friday, Amgen, Inc. (NASDAQ: AMGN) filed an intellectual property rights (IPR) suit against AbbVie Inc (NYSE: ABBV)’s ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.